Biotech candidates
发表于 : 2014-04-22 14:18这其中有DQ 最着迷的 MannKind。 大家以后不妨讨论一下怎么赌它们的走向 post-FDA news 。
07/15/2014 MannKind Corp. MNKD AFREZZA Inhalation Powder (NDA) FDA decision on AFREZZA Inhalation Powder to improve glycemic control in adult patients suffering from type I or type II diabetes
06/25/2014 AstraZeneca PLC AZN.L, AZN Olaparib capsules (NDA) FDA panel to review Olaparib as monotherapy for relapsed ovarian cancer
04/30/2014 The Medicines Co. MDCO Cangrelor (NDA) FDA decision on Cangrelor for use in patients undergoing percutaneous coronary intervention or cardiac stent procedures or those that require bridging from oral antiplatelet therapy to surgery
-Drug Status
04/28/2014 Flamel Technologies SA FLML Undisclosed Éclat product (NDA) FDA decision on the undisclosed Éclat product
04/25/2014 POZEN Inc. POZN PA32540/PA8140 (NDA) FDA decision on PA32540/PA8140 for the secondary prevention of cardiovascular disease in patients at risk for aspirin-induced gastric ulcers
07/15/2014 MannKind Corp. MNKD AFREZZA Inhalation Powder (NDA) FDA decision on AFREZZA Inhalation Powder to improve glycemic control in adult patients suffering from type I or type II diabetes
06/25/2014 AstraZeneca PLC AZN.L, AZN Olaparib capsules (NDA) FDA panel to review Olaparib as monotherapy for relapsed ovarian cancer
04/30/2014 The Medicines Co. MDCO Cangrelor (NDA) FDA decision on Cangrelor for use in patients undergoing percutaneous coronary intervention or cardiac stent procedures or those that require bridging from oral antiplatelet therapy to surgery
-Drug Status
04/28/2014 Flamel Technologies SA FLML Undisclosed Éclat product (NDA) FDA decision on the undisclosed Éclat product
04/25/2014 POZEN Inc. POZN PA32540/PA8140 (NDA) FDA decision on PA32540/PA8140 for the secondary prevention of cardiovascular disease in patients at risk for aspirin-induced gastric ulcers
